11,434 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,434 shares of the company’s stock, valued at approximately $1,927,000.

Several other institutional investors and hedge funds have also bought and sold shares of NBIX. Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. DJE Kapital AG acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $28,000. Basecamp Wealth Advisors LLC boosted its holdings in Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in Neurocrine Biosciences during the 1st quarter worth about $33,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after buying an additional 202 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the sale, the insider owned 54,729 shares of the company’s stock, valued at approximately $9,829,328.40. This trade represents a 15.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the completion of the sale, the director directly owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. The trade was a 32.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 376,612 shares of company stock worth $59,493,355. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $152.72 on Friday. The stock has a market capitalization of $15.52 billion, a PE ratio of 22.39, a price-to-earnings-growth ratio of 0.54 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The business has a 50 day simple moving average of $167.98 and a 200-day simple moving average of $148.23.

Analyst Ratings Changes

A number of brokerages have recently commented on NBIX. Guggenheim upped their target price on Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein initiated coverage on shares of Neurocrine Biosciences in a research note on Friday, May 22nd. They set an “outperform” rating and a $221.00 price objective on the stock. Truist Financial boosted their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, TD Cowen increased their price target on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $200.86.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.